Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies.
Publication/Presentation Date
2-1-2019
Abstract
Donor-specific HLA antibodies (DSAs) have been associated with an increased risk of graft failure. To decrease DSA levels and reduce the risk of graft failure in haploidentical cord blood transplantation recipients, we studied the effect of bortezomib (BTZ) and i.v. immune globulin (IVIG) pretransplantation. Between 2012 and 2016, 14 patients with a DSA level >2000 mean fluorescence intensity (MFI) to 1 or more mismatched HLA alleles of haploidentical donors, cord blood donors, or both were treated with BTZ and IVIG. Fourteen patients received a median of 4 doses (range, 2 to 8 doses) of BTZ 1.3 mg/m
Volume
25
Issue
2
First Page
60
Last Page
60
ISSN
1523-6536
Published In/Presented At
Choe, H., Gergis, U., Hsu, J., Phillips, A., Shore, T., Christos, P., van Besien, K., & Mayer, S. (2019). Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25(2), e60–e64. https://doi.org/10.1016/j.bbmt.2018.10.018
Disciplines
Medicine and Health Sciences
PubMedID
30661542
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article